Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment
Schwarzbich, M.-A.; Schöning, T.; Cremer, M.; Lisenko, K.; Ho, A.D.; Witzens-Harig, M.
Leukemia and Lymphoma 57(7): 1723-1726
2016
ISSN/ISBN: 1029-2403
PMID: 26980422
DOI: 10.3109/10428194.2015.1113274
Accession: 057738642
PDF emailed within 0-6 h: $19.90
Related References
Pohlen, M.; Gerth, H.U.; Liersch, R.; Koschmieder, S.; Mesters, R.M.; Kessler, T.; Appelmann, I.; Müller-Tidow, C.; Berdel, W.E. 2011: Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma American Journal of Hematology 86(12): E61-E64Mato, A.; Feldman, T.; Zielonka, T.; Singavi, A.; Gadaletta, G.; Waksmundzki, K.; Bhattacharyya, P.; Chow, K.F.; Yang, X.; Panush, D.; Agress, H.; Rosario, M.; Howlett, C.; Pecora, A.; Goy, A. 2013: Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma Leukemia and Lymphoma 54(12): 2606-2612
Xu, W.; Li, J.-Y.; Zhang, Z.-H.; Qiu, H.-X.; Qian, S.-X.; Wu, H.-X.; Lu, H.; Sheng, R.-L. 2008: Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(4): 933-937
Jurczak, W.; Ochrem, B.; Giza, A.; Zimowska-Curyło, D.; Górecki, T.; Boguradzki, P.; Knopińska-Posłuszny, W.; Stella-Hołowiecka, B.; Walewski, J.; Joks, M.; Wróbel, T.; Zaucha, J.M. 2015: Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group Polskie Archiwum Medycyny Wewnetrznej 125(10): 741-748
Haioun, C.; Mounier, N.; Emile, J.F.; Ranta, D.; Coiffier, B.; Tilly, H.; Récher, C.; Fermé, C.; Gabarre, J.; Herbrecht, R.; Morchhauser, F.; Gisselbrecht, C. 2009: Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Annals of Oncology: Official Journal of the European Society for Medical Oncology 20(12): 1985-1992
Kasahara, S.; Hara, T.; Tsurumi, H.; Goto, N.; Kitagawa, J.-I.; Kanemura, N.; Yoshikawa, T.; Goto, H.; Fukuno, K.; Yamada, T.; Sawada, M.; Takahashi, T.; Takami, T.; Moriwaki, H. 2011: Phase Ii study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma Leukemia and Lymphoma 52(4): 629-634
Glass, B.; Ziepert, M.; Reiser, M.; Freund, M.; Trümper, L.; Metzner, B.; Feller, A.; Loeffler, M.; Pfreundschuh, M.; Schmitz, N. 2010: High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma Annals of Oncology: Official Journal of the European Society for Medical Oncology 21(11): 2255-2261
Kato, J.; Mori, T.; Yokoyama, K.; Tsukada, Y.; Ueda, T.; Shimizu, T.; Okamoto, S. 2011: Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma Bone Marrow Transplantation 46(7): 923-928
Mandal, P.K.; Dolai, T.K.; Bagchi, B.; Ghosh, M.K.; Bose, S.; Bhattacharyya, M. 2014: B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen Indian Journal of Pediatrics 81(10): 1092-1094
Oki, Y.; Westin, J.R.; Vega, F.; Chuang, H.; Fowler, N.; Neelapu, S.; Hagemeister, F.B.; McLaughlin, P.; Kwak, L.W.; Romaguera, J.E.; Fanale, M.; Younes, A.; Rodriguez, M.A.; Orlowski, R.Z.; Wang, M.; Ouzounian, S.T.; Samaniego, F.; Fayad, L. 2013: Prospective phase Ii study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma British Journal of Haematology 163(5): 611-620
Murayama, T.; Fukuda, T.; Okumura, H.; Sunami, K.; Sawazaki, A.; Maeda, Y.; Tsurumi, H.; Uike, N.; Hidaka, T.; Takatsuka, Y.; Eto, T.; Tsuda, H.; Fujisaki, T.; Miyamoto, T.; Tsuneyoshi, N.; Iyama, S.; Nagafuji, K.; Harada, M. 2016: Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase Ii study (JSCT-NHL04) International Journal of Hematology 103(6): 676-685
Li, Y.; Yimamu, M.; Wang, X.; Zhang, X.; Mao, M.; Fu, L.; Aisimitula, A.; Nie, Y.; Huang, Q. 2014: Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression International Journal of Hematology 99(1): 79-86
Lefrère, F.ço.; Bastit-Barrau, D.; Hequet, O.; Bourin, P.; Mathieu-Nafissi, S.; Bohbot, A.; Tilly, H.é; Salles, G.; Fermé, C.; Lapierre, V.ér.; Fornecker, L.; Micléa, J.-M.; Isebaert, L.; Bologna, S.; Fitoussi, O.; Mounier, N.; Haioun, C. 2013: Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients Transfusion 53(1): 115-122
Haioun, C.; Mounier, N.; Emile, J.F.; Feugier, P.; Coiffier, B.; Tilly, H.; Recher, C.; Ferme, C.; Gabarre, J.; Herbrecht, R.; Morschhauser, F.; Gisselbrecht, C. 2003: Rituximab vs nothing after high-dose consolidative first-line chemotherapy with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma Results of the first interim analysis of the randomized LNH98-B3 GELA Study Blood 102(11): 399a
Strüßmann, T.; Fritsch, K.; Baumgarten, A.; Fietz, T.; Engelhardt, M.; Mertelsmann, R.; Ihorst, G.; Duyster, J.; Finke, J.ür.; Marks, R. 2017: Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation British Journal of Haematology 178(6): 927-935